Articles related to LUNG CANCER

The results of the WU-KONG6 study offer hope for NSCLC patients with EGFR exon20 insertion mutations, demonstrating the substantial antitumor efficacy of sunvozertinib.

Clinicians are eyeing the increased survival odds associated with Tagrisso, a targeted therapy for early-stage NSCLC patients. This revelation may shift the narrative on post-operative treatment protocols, promoting wider acceptance in oncological circles.

Understand the profound implications of Dr. Vidal’s latest research on racial disparities in NGS testing for advanced non-small cell lung cancer, revealing a systemic issue that spans across practices and extends to the level of individual physicians.

A deeper understanding of the impact of smoking and vaping on cancer survivor symptom burdens might open new avenues for tailoring smoking cessation interventions. Uncover how these findings could challenge common assumptions and transform symptom management strategies in our recent article.

Pivotal Role of Adjuvant Osimertinib in EGFR-Mutated NSCLC Survival A groundbreaking phase 3 trial reveals the significant impact of adjuvant osimertinib on overall survival rates in patients with resected, EGFR-mutated, stage IB to IIIA non-small-cell lung cancer (NSCLC). “Adjuvant osimertinib provided a significant overall survival benefit among patients with completely resected, EGFR-mutated, stage IB to IIIA NSCLC.” ADAURA ClinicalTrials.gov number, NCT02511106

Pembrolizumab Enhances Outcomes in Early-Stage NSCLC: A Phase 3 Trial Analysis In the pursuit of improved treatment outcomes for early-stage non-small-cell lung cancer (NSCLC), a phase 3 trial evaluated the efficacy of perioperative pembrolizumab. “Among patients with resectable, early-stage NSCLC, neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab significantly improved event-free survival, major pathological response, and pathological complete response as compared with neoadjuvant chemotherapy alone followed by surgery.” Study Conclusions, KEYNOTE-671 ClinicalTrials.gov number, NCT03425643